In one aspect, the present disclosure refers to use of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, in the manufacture of a medicament for the treatment of a solid tumor cancer, wherein said medicament is to be administered:

a) at a loading dose of 75-100 mg/dose twice or three times per week for one or two weeks during a 28 day cycle; followed by

b) a maintenance dose of 50 mg/dose three times per week;

wherein, during the administration of the loading dose, 1-80 mg/day of a corticosteroid is to be administered.

Disclosed is a method of treating a solid tumor cancer comprising administering to a patient in need of treatment 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof,

a) a loading dose of at least one dose and up to 12 doses at 75-150 mg/dose administered twice or three times per week during a 28 day cycle; followed by

b) a maintenance dose of 50 mg/dose administered three times per week; and optionally

c) administering, during administration of the loading dose, 1-50 mg/day of a corticosteroid;

WE CLAIM:

1. Use of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, in the manufacture of a medicament for the treatment of a solid tumor cancer, wherein said medicament is to be administered:
    a) at a loading dose of 75-100 mg/dose twice or three times per week for one or two weeks during a 28 day cycle; followed by
    b) a maintenance dose of 50 mg/dose three times per week;
    wherein, during the administration of the loading dose, 1-80 mg/day of a corticosteroid is to be administered.
2. The use of claim 1, wherein the corticosteroid is to be administered for one week or two weeks.
3. The use of claim 1 or claim 2, wherein the corticosteroid is to be administered at a dose of 1-50 mg/day.
4. The use of any one of claims 1-3, wherein the corticosteroid is to be administered at a dose of 20 mg/day.
5. The use of any of claims 1-4, wherein the corticosteroid is selected from the group consisting of hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, and prednisone.
6. The use of any one of claims 1-4, wherein the corticosteroid is prednisone.
7. The use of any of claims 1-6, wherein said loading dose is at least 2 doses and up to 6 doses.
8. The use of any of claims 1-6, wherein said loading dose is 2 doses or 3 doses.
9. The use of any one of claims 1-6, wherein said loading dose is 4 doses or 6 doses.
10. The use of any of claims 1-9, wherein the maintenance dose is to be administered over any remaining days of the 28 day cycle following administration of the loading dose and, optionally, over one or more additional 28 day cycles.
11. The use of any of claims 1-10, wherein said solid tumor cancer is selected from the group consisting of triple negative breast cancer, breast cancer, ovarian cancer, melanoma, lung cancer, non-small cell lung cancer, pancreatic cancer,

glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral squamous cell carcinoma, skin cancer, medulloblastoma, hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, desmoid tumor, soft tissue sarcoma, leiomyosarcoma, and adenoid cystic carcinoma.

12. The use of any one of claims 1-11, wherein said solid tumor cancer is an advanced or metastatic solid tumor cancer.